Teleflex account plan
Healthcare product provider
At a glance
Teleflex makes single-use medical devices for critical care and surgery; FY2025 continuing revenue $1,992.7 million, 2026 guide $2,256-2,276 million.
Teleflex Incorporated, based in Wayne, PA, designs, manufactures and supplies single-use medical devices for critical care and surgical procedures, sold to hospitals through a direct sales force and distributors; major plants are in the Czech Republic, Malaysia, Mexico and the U.S. FY2025 net revenues from continuing operations were $1,992.7 million (+17.2%), boosted by the acquired BIOTRONIK Vascular Intervention business, while the group posted a net loss of $905.6 million driven by impairments on businesses being sold. After selling OEM in August 2026 and with Acute Care and Interventional Urology under sale, it now runs three global units: Vascular, Interventional and Surgical. It employed approximately 15,500 people at December 31, 2025; Jason Weidman has been President and CEO since June 8, 2026.
Business units
Vascular
about 46% of FY2025 continuing revenue ($917.7 million)Arrow catheters and tip positioning systems, EZ-IO and Arrow FAST1 intraosseous access, and QuikClot hemostatic products. Q3 2026 revenue was $243.5 million (+4.7%) with operating profit up 17.3%; EZPLAZ freeze-dried plasma was approved by the FDA in July 2026.
Interventional
about 33% of FY2025 continuing revenue ($647.8 million)Coronary and peripheral catheters, structural heart support, the MANTA closure device and, since June 30, 2025, BIOTRONIK VI stents and drug-coated balloons. Q3 2026 revenue was $210.3 million (-2.6%) as the VI integration lagged; Jason Fontana leads the unit.
Surgical
about 21% of FY2025 continuing revenue ($418.2 million)Ligation clips, laparoscopic closure, a powered bariatric stapler and ENT and cardio-thoracic instruments (Weck, Pleur-Evac, Titan SGS). Q3 2026 revenue was $114.0 million (+4.2%).
Acute Care, Interventional Urology and OEM (divested or being divested)
FY2025 revenue of $1,304.3 million, reported as discontinued operations. OEM was sold to Montagu and Kohlberg on August 3, 2026; Acute Care and Interventional Urology (UroLift, Barrigel) are being sold to Intersurgical for about $530 million, possibly closing in 2027.
Strategic priorities
- Complete the transformation
- Close the Acute Care and Interventional Urology sale, targeted by end of 2026 but possibly 2027 after an FTC second request, and finish integrating Interventional.
- Simpler operating model
- Move from a geographic matrix to three global business units, each owning its strategy, resources and results.
- Raise the growth profile through innovation
- R&D raised to close to 8% of revenue, with Freesolve resorbable magnesium scaffold (BIOMAG data due late 2027) and EZPLAZ, a U.S. opportunity of at least $200 million.
- Return capital and cut debt
- Plan of $1 billion of buybacks and $800 million of debt reduction from divestiture proceeds; net leverage about 1.4x in Q3 2026.
- Margin step-up
- Adjusted operating margin about 20.0% in 2026, approximating 23% in the first year after the Acute Care and IU close, with about $50 million of annual restructuring savings.
Latest results
In Q3 2026 (quarter ended September 30, 2026) revenue from continuing operations was $567.8 million, up 0.2% reported and 3.0% on a pro forma adjusted constant currency basis. Gross margin rose to 65.0% from 51.5%, helped by the end of VI inventory step-up and a $25.3 million IEEPA tariff refund, and adjusted diluted EPS was $2.63 (vs $1.89). Net income was $927.4 million including the gain on the OEM sale. Teleflex kept its 2026 pro forma constant currency growth guidance at 3.5%-4.5%, cut GAAP revenue guidance to $2,256-2,276 million on FX and raised adjusted EPS guidance to $7.50-$7.75.
Investments and deals
- BIOTRONIK Vascular Intervention acquisition
- Acquired June 30, 2025 for a net €704.3 million ($825.2 million), adding $202.4 million of 2025 revenue.
- OEM divestiture
- Closed August 3, 2026: net cash proceeds of $1.5 billion ($1.25 billion after tax).
- Share repurchases
- 4.6 million shares bought for $600.0 million in 2026 to the filing date, with $400.0 million left on the $1 billion authorization.
- Restructuring plans
- VI integration plan targeting $24-30 million of annual savings by end of 2028, and the Strategic Divestitures plan targeting $48-52 million by mid-2028.
- New ERP
- Ongoing development of a new ERP solution raised IT costs.
Challenges and risks
- Slow VI integration
- Order-to-cash, distributor and sales force transitions held Interventional back; open territories are down 63% from peak and new reps need about 6 months to become productive.
- Tariffs
- Tariff costs of a little over $30 million in 2026, with similar levels expected in 2027.
- Divestiture timing
- The Acute Care and IU sale faces an FTC second request and may slip into 2027, with stranded costs to remove.
- GLP-1 impact on bariatric surgery
- Reduced bariatric procedures led to a $100.0 million impairment on the Titan SGS asset group in 2025.
- China procurement and sterilization rules
- China volume-based procurement cuts prices, and EPA ethylene oxide emission standards affect contract sterilizers Teleflex depends on.
What leadership says
“a meaningful step-up in adjusted earnings per share”
“this is absolutely not a product issue”
“a more focused, agile and growth-oriented Teleflex”
“we're confident this transaction will be completed.”
Where a supplier can help
- Order-to-cash and distributor transitions
- The VI integration challenge sits in ordering, distributor and consignment processes; supply chain, ERP and order management partners can help close it.
- Sales force onboarding
- Refilling territories with reps who need about 6 months to ramp creates demand for sales training, enablement and territory planning tools.
- Stranded cost removal
- The Strategic Divestitures restructuring plan targets $48-52 million of savings, favouring shared services, IT and process simplification vendors.
- Clinical trial and R&D support
- Higher R&D spend and the BIOMAG III U.S. pivotal trial call for CROs, clinical data and regulatory services.
- Tariff and supply chain optimisation
- Tariff mitigation through supply chain changes and more USMCA-compliant products needs sourcing, trade compliance and logistics expertise.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Teleflex?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Teleflex Incorporated Annual Report on Form 10-K for fiscal year 2025
- Teleflex is a Wayne, PA medical technology company designing, manufacturing and supplying single-use medical devices for critical care and surgical procedures, sold to hospitals and healthcare providers through its direct sales force and distributors; major plants are in the Czech Republic, Malaysia, Mexico and the U.S.
- FY2025 net revenues from continuing operations were $1,992.7 million, up 17.2%, mainly from $202.4 million contributed by the acquired BIOTRONIK Vascular Intervention (VI) business; gross margin fell to 56.2% from 61.0%.
- In February 2025 Teleflex announced a strategic transformation; on December 9, 2025 it agreed to sell Acute Care and Interventional Urology to Intersurgical Ltd ($530 million) and OEM to Montagu and Kohlberg (about $1.5 billion), $2.0 billion in cash in total, now reported as discontinued operations (FY2025 revenue $1,304.3 million).
- Continuing portfolio by product category in FY2025: Vascular $917.7 million (Arrow catheters, EZ-IO, QuikClot), Interventional $647.8 million (GuideLiner, MANTA, VI stents and drug-coated balloons), Surgical $418.2 million (Weck, Pleur-Evac, Titan SGS).
- Net loss of $905.6 million in FY2025, driven by a $964.2 million loss from discontinued operations (goodwill impairments and a $747.1 million valuation allowance on the disposal group); a $100.0 million Titan SGS impairment hit continuing operations, linked to GLP-1 drugs reducing bariatric surgery.
- Expected net after-tax proceeds of about $1.8 billion go mainly to share repurchases and debt paydown; the Board authorized a $1.0 billion buyback on December 9, 2025.
- Leadership change: CEO and chairman Liam J. Kelly left on January 8, 2026; Stuart A. Randle became Interim President and CEO, Stephen K. Klasko independent chair; John R. Deren is CFO.
- Restructuring: the VI Business integration plan targets $24-30 million annual savings and the Strategic Divestitures restructuring plan $48-52 million, both running to 2028.
- Key risks: execution of the transformation and stranded costs, U.S. tariffs (EU imports and non-USMCA-compliant Mexican products), China volume-based procurement, ethylene oxide sterilization rules, U.S. distributor destocking and the CEO transition.
- Teleflex Incorporated Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter ended September 30, 2026) net revenues from continuing operations were $567.8 million (+0.2%); nine-month revenues $1,686.4 million (+18.4%), helped by $198.1 million from the acquired VI business.
- From Q3 2026 Teleflex reports three global product segments instead of geographic ones: Vascular ($243.5 million, +4.7%), Interventional ($210.3 million, -2.6%) and Surgical ($114.0 million, +4.2%).
- Q3 gross margin rose to 65.0% from 51.5%, helped by non-recurrence of VI inventory step-up and a $25.3 million IEEPA tariff refund, partly offset by quality remediation costs.
- The OEM sale to Montagu and Kohlberg closed on August 3, 2026: net cash proceeds $1.5 billion ($1.3 billion after tax) and a $1.0 billion pre-tax gain; Q3 net income was $927.4 million.
- The Acute Care and IU sale to Intersurgical (gross proceeds about $530 million) is expected by end of 2026 but may slip into 2027.
- Proceeds repaid the $700 million term loan A-2 and $490.0 million of the revolver; 4.6 million shares repurchased for $600.0 million in 2026 to the filing date, $400.0 million left on the $1 billion authorization.
- Leadership: Jason Weidman became President and CEO on June 8, 2026; Andrew A. Krakauer is Chairman; Sean M. Salmon joined the Board on September 8, 2026.
- Strategic Divestitures restructuring plan now $34-40 million of charges for $48-52 million of annual pre-tax savings by mid-2028.
- Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook
- Teleflex's Q3 2026 release (November 5, 2026): revenue from continuing operations $567.8 million, +0.2% reported and +3.0% pro forma adjusted constant currency; GAAP diluted EPS $1.30, adjusted diluted EPS $2.63 (vs $1.89).
- Pro forma adjusted constant currency growth by segment: Vascular +4.6%, Interventional +0.2%, Surgical +5.1%; nine months +4.2% in total.
- 2026 guidance: pro forma adjusted constant currency revenue growth maintained at 3.5%-4.5%; GAAP revenue growth cut to 13.2%-14.2% on FX (revenue $2,256-2,276 million); adjusted EPS raised to $7.50-$7.75, GAAP EPS $2.84-$3.09.
- Adjusted operating margin assumption for 2026 about 20.0% (19.0% previously), including $16.5 million of IEEPA tariff refunds for 2026.
- CEO Jason Weidman: priorities are delivering the transformation (divestitures and VI integration), organizational effectiveness and a higher growth profile; he expects "a meaningful step-up in adjusted earnings per share in 2027".
- Innovation: Freesolve resorbable magnesium scaffold got FDA Breakthrough Device Designation for PCI; EZPLAZ freeze-dried plasma seen as a U.S. market opportunity of at least $200 million.
- Capital: $350 million repurchased since July 1, 2026; $400 million left of the $1 billion authorization; OEM sale brought $1.25 billion after-tax proceeds.
- Teleflex Q3 2026 Earnings Call Transcript
- Q3 2026 earnings call (November 5, 2026) with CEO Jason Weidman and CFO John Deren: pro forma adjusted constant currency revenue growth 3%, adjusted operating margin 25%, adjusted EPS $2.63 (+39.2%).
- Weidman's three priorities: strengthen the foundation (close the Acute Care and IU divestiture, finish the Interventional integration), accelerate organizational effectiveness (global business units, simpler operating model), elevate growth (innovation and capital allocation).
- Teleflex now runs three global business units, Vascular, Interventional and Surgical; Weidman said the old geographic structure created "a complex matrix".
- VI integration: about 90% of VI customers moved to Teleflex ordering, 87% of the indirect business under Teleflex distributors, open sales territories down 63% from peak; Jason Fontana leads Interventional.
- R&D raised from about 5%-6% of revenue to close to 8%; Freesolve has FDA breakthrough device designation and BIOMAG trial data are due late 2027; EZPLAZ U.S. opportunity at least $200 million, U.S. government and military first.
- Capital: $1 billion buyback and $800 million debt reduction; net leverage about 1.4x; operating margin expected to approximate 23% in the first year after the Acute Care and IU close.
- Tariffs a little over $30 million in 2026 and expected to be similar in 2027; no 2027 guidance until the next call.
- Teleflex (TFX) Q2 2026 Earnings Call Transcript
- Q2 2026 earnings call (August 6, 2026), Jason Weidman's first as CEO (two months in), with CFO John Deren: revenue $570.3 million, +28.9% reported and +4.7% pro forma adjusted constant currency; adjusted EPS $1.76.
- Vascular $246.3 million (+8%) and Surgical $112.1 million (+9.2%) were strong; Interventional $211.9 million (-1%) suffered from a slower VI integration.
- Weidman named three transient integration issues, order-to-cash, distributor and sales force transitions, saying "this is absolutely not a product issue"; full integration pushed through the second half of 2026.
- 2026 guidance: constant currency growth cut to 3.5%-4.5% (from 4.5%-5.5%), entirely on Interventional; adjusted EPS raised to $6.90-$7.20; adjusted operating margin about 19%; steady-state margin about 23%.
- OEM divestiture closed ($1.5 billion, $1.25 billion after tax); $250 million ASR started August 7; $700 million term loan repaid; plan of $1 billion buybacks and $800 million debt reduction.
- Innovation: EZPLAZ freeze-dried plasma FDA approval in late July (U.S. government and military first); Freesolve BIOMAG-II enrollment completed, BIOMAG-III U.S. pivotal trial started; R&D at 7.9% of sales in H1 2026.
Questions about Teleflex
What does Teleflex do?
Teleflex designs and manufactures single-use medical devices for critical care and surgical procedures, organised into Vascular, Interventional and Surgical units.
What is Teleflex's revenue?
FY2025 net revenues from continuing operations were $1,992.7 million; 2026 guidance is $2,256-2,276 million.
How many employees does Teleflex have?
Approximately 15,500 at December 31, 2025, before the divestitures.
Who leads Teleflex?
Jason Weidman has been President and CEO since June 8, 2026; John R. Deren is CFO and Andrew A. Krakauer is Chairman.
What is Teleflex's strategy?
Teleflex is divesting Acute Care, Interventional Urology and OEM to focus on three global units, raising R&D, simplifying its operating model and returning capital through buybacks and debt reduction.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)